AbbVie Inc.
Close on Nov 2, 2026Market cap $510.41BP/E 81.6Yield 2.30%
AbbVie Immunology Portfolio by Year
Immunology Portfolio — International net revenues ($M) ($M)
AbbVie Immunology Portfolio: $6,202M in FY2025, up 19.4% from a year earlier.
Where the FY2025 figure comes from
“|| Immunology | 24,204 | 6,202 | 30,406 | 12.7 | 19.4 | 14.0 | 18.8 | 13.9”
Source: Form 8-K (abbv-20251231xexhibit991.htm, filed 2026-02-04) ↗
Reported in Form 10-Q / 10-K Segment & Revenue Disaggregation Note & Form 8-K Key Product Revenues.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Immunology Portfolio — International net revenues ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 6,202 | +19.4% | Form 8-K (abbv-20251231xexhibit991.htm, filed 2026-02-04) ↗ |
| FY2024 | Dec 31, 2024 | 5,195 | +18.1% | Form 8-K (abbv-20241231xexhibit991.htm, filed 2025-01-31) ↗ |
| FY2023 | Dec 31, 2023 | 4,399 | +9.2% | Form 8-K (abbv-20231231xexhibit991.htm, filed 2024-02-02) ↗ |
| FY2022 | Dec 31, 2022 | 4,027 | -4.1% | Form 8-K (abbv-20221231xexhibit991.htm, filed 2023-02-09) ↗ |
| FY2021 | Dec 31, 2021 | 4,197 | +4.8% | Form 8-K (abbv-20211231xexhibit991.htm, filed 2022-02-02) ↗ |
| FY2020 | Dec 31, 2020 | 4,003 | -8.0% | Form 8-K (abbv-20201231xexhibit991.htm, filed 2021-02-03) ↗ |
| FY2019 | Dec 31, 2019 | 4,349 | -30.4% | Form 8-K (abbv-20191231xexhibit9.htm, filed 2020-02-07) ↗ |
| FY2018 | Dec 31, 2018 | 6,251 | – | Form 8-K (abbv-20181231xexhibit991.htm, filed 2019-01-25) ↗ |
Breakdown
What makes up immunology Portfolio
Cite this data
StockData. (2026). AbbVie Immunology Portfolio ($M), annual FY2018–FY2025 [Data set]. Compiled from AbbVie SEC filings and investor materials. https://stockdatahq.com/stocks/abbv/kpis/ta-imm-intl
See every metric in the AbbVie KPI table. Data updated Oct 26, 2026.